-
Janney Upgrades bluebird bio Ahead Of Sickle Cell Presentation
Monday, November 5, 2018 - 1:09pm | 418Shares of bluebird bio Inc. (NASDAQ: BLUE) surged over 13 percent last week as the company announced plans to release abstracts at the American Society of Hematology meeting in December. The Analyst Janney analyst Yun Zhong upgraded bluebird from Neutral to Buy and maintained a $170 price...